Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.80 |
| ▸ | EGFR | P00533 | 7/20 | 0.66 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.66 |
| ▸ | AURKA | O14965 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | IDH2 | P48735 | 2/20 | 0.57 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374332 | 0.92 | THRB (0.74) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL4239042 | 0.91 | THRB (0.68) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL374140 | 0.89 | THRB (0.70) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL19420148 | 0.89 | THRB (0.70) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL13778007 | 0.89 | THRB (1.00) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL30141460 | 0.85 | THRB (0.65) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL4239038 | 0.85 | AURKA (0.70) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL8798662 | 0.84 | AURKA (0.63) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL4238979 | 0.83 | AURKA (0.67) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL7782959 | 0.83 | THRB (0.62) | THRBEGFRERBB4AURKAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | claimed |
| EP-1943233-A2 | COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2008-07-16 | — | — | EP | claimed |
| WO-2007056151-A2 | PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | claimed |
| EP-0733045-B1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | EP | claimed |
| JP-H09506363-A | — | — | 1997-06-24 | — | — | JP | claimed |
| EP-0733045-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | claimed |
| WO-1995015952-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-15 | — | — | WO | claimed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
| EP-1943233-A2 | COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007056151-A2 | PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
| EP-0733045-B1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | EP | disclosed |
| US-5880130-A | TREATMENT OF CELL-PROLIFERATION DISEASES | ZENECA LIMITED (GB) | 1999-03-09 | — | — | US | disclosed |
| EP-0733045-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015952-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ERBB2, BMX, ERBB3 | THRB 461/4885EGFR 42/4885ERBB4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.